The exploration of the efficacy and possible mechanisms of paroxetine combined with liraglutide in the treatment of depression associated with obesity.

Start Date28 Nov 2025

Sponsor / Collaborator

Southeast University Affiliated Zhonda Hospital

NCT07225816

/ RecruitingPhase 1

Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide

The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.

Start Date07 Nov 2025

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Liraglutide

100 Translational Medicine associated with Liraglutide

100 Patents (Medical) associated with Liraglutide

3,910

Literatures (Medical) associated with Liraglutide

01 Jan 2026·Obesity

One Year of Exercise After Weight Loss Increases Postprandial GLP ‐1 Secretion in Contrast to Usual Activity or GLP ‐1 Receptor Agonist Treatment

Article

Author: Stallknecht, Bente ; Madsbad, Sten ; Juhl, Christian Rimer ; Holst, Jens Juul ; Sandsdal, Rasmus Michael ; Byberg, Sarah ; Torekov, Signe Sørensen ; Hartmann, Bolette ; Jensen, Simon Birk Kjær ; Holt, Joachim ; Janus, Charlotte ; Jørgensen, Julie Rehné

ABSTRACT:

Objective:

Incretin‐based obesity medication maintains weight loss by mimicking the appetite‐inhibiting hormone GLP‐1. Interestingly, chronic exercise may improve postprandial appetite control by increasing late postprandial secretion of endogenous GLP‐1. Therefore, we investigated whether an exercise program after weight loss could increase late‐phase postprandial GLP‐1 secretion.

Methods:

This study is an exploratory analysis of adults with obesity ( n = 195) who lost 13.1 kg on a low‐calorie diet and were randomized to 52 weeks of either usual activity, moderate‐to‐vigorous intensity exercise, the GLP‐1 receptor agonist liraglutide (3.0 mg/day), or the combination. The primary endpoint was change in late‐phase GLP‐1 response to a 3‐h liquid mixed meal test before and after diet‐induced weight loss and after 1 year of intervention.

Results:

Diet‐induced weight loss did not change late‐phase GLP‐1 response (3%; 95% CI, −4%–10%). One year of exercise increased late‐phase postprandial GLP‐1 response within the group by 37% (95% CI, 20%–57%), and this increase was 25% greater (95% CI, 3%–51%, p = 0.02) compared to the usual activity group. Late‐phase postprandial GLP‐1 response was unchanged in both groups treated with GLP‐1 receptor agonist compared to placebo.

Conclusions:

One year of exercise increased late‐phase postprandial GLP‐1 response, which may prevent increased appetite after weight loss and thereby weight regain.

Trial Registration:

EudraCT number: 2015–005585‐32; ClinicalTrials.gov identifier: NCT04122716

01 Jan 2026·TOXICON

Computational modelling the impact of GLP-1 receptor agonists on botulinum toxin A: Evidence for reduced treatment durability across neurologic and aesthetic indications

Article

Author: Rao, Parinitha ; Joseph, John H ; Ahmed, Munim ; Rahman, Eqram ; Carruthers, Jean DA ; Webb, William Richard ; Wu, Woffles Tl ; Michon, Alain

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed metabolic and aesthetic medicine, yet their potential influence on botulinum toxin type A (BoNT-A) pharmacodynamics remains unexplored. Using the AesthetiSIM™ microsimulation platform, a transparent, parameterized in-silico model was developed to estimate whether GLP-1-related changes in metabolism and neuromuscular recovery could alter toxin durability. Twenty-five thousand virtual patients were generated, representing two domains of BoNT-A use: chronic migraine (n = 20,000) and masseter prominence (n = 5000). Virtual subjects were randomly assigned to semaglutide, tirzepatide, liraglutide, dulaglutide, or control conditions, and simulated over one year under standardized 100-unit BoNT-A dosing. The framework incorporated three mechanistic domains-synaptic modulation via cAMP-PKA-mediated SNAP-25 phosphorylation, lean-mass reduction affecting diffusion kinetics, and systemic metabolic variability reflecting diabetic or rapid-weight-loss phenotypes. In chronic migraine, mean BoNT-A duration declined from 14.0 ± 2.3 weeks in controls to 12.6, 12.5, 12.2, and 11.8 weeks across GLP-1 exposures (all p < 0.001; hazard ratio range 1.54-1.95). In masseter prominence, mean duration decreased from 20.1 ± 2.9 weeks to 17.3, 17.0, 16.7, and 16.2 weeks, with hazard ratios 1.72-2.08. Early wear-off and uncovered symptomatic periods rose proportionally across agents, with the hierarchy tirzepatide > liraglutide > dulaglutide > semaglutide. Sensitivity analyses indicated that approximately 55 % of the reduction in duration was attributable to synaptic modulation, 30 % to lean-mass decline, and 15 % to metabolic variability. These findings suggest a biologically plausible interaction between GLP-1 signalling and BoNT-A recovery dynamics. The results are exploratory and derive entirely from computational modelling rather than clinical observation. Experimental validation-such as neuronal culture assays or prospective patient cohorts-is required before any modification of treatment intervals or dosing practices can be considered.

01 Jan 2026·DIABETES OBESITY & METABOLISM

Hypothalamic RASA1 /Ras/ AKT / GnRH axis reprogramming mediates GLP ‐ 1RA 's central rescue of PCOS HPG dysfunction

Article

Author: He, Jinhong ; Yang, Linlin ; Ma, Huijuan ; Wang, Xing ; Zhang, Xincheng ; Guo, Na ; Li, Hongyun ; Zhou, Huanhuan

Abstract:

Aim:

Polycystic ovary syndrome (PCOS), characterised by hyperandrogenaemia and hypothalamic–pituitary–gonadal (HPG) axis dysregulation driven by gonadotropin‐releasing hormone (GnRH) neuronal hyperactivity, remains mechanistically enigmatic, with limited targeted therapies. Although glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) show potential in alleviating PCOS reproductive dysfunction, their presumed mechanisms have been confined to peripheral metabolic modulation.

Materials and Methods:

Using liraglutide as a representative GLP‐1RA, this study elucidated the central control mechanism mediating GLP‐1RA's therapeutic effects in PCOS through systematically scanning hypothalamic protein profiles combined with pharmacology gain‐/loss‐of‐function experiments.

Results:

In letrozole‐induced PCOS rats, GLP‐1RA administration significantly reduced serum testosterone and luteinizing hormone levels, partially restored oestrous cyclicity, and ameliorated ovarian follicular abnormalities. Hypothalamic proteomic mapping revealed that GLP‐1RA counteracts hyperandrogenism‐induced signalling perturbations, with network analysis identifying RASA1 as the critical hub connecting therapeutic responses to GnRH regulation. Mechanistically, RASA1 exerts dual control over GnRH neurons—directly suppressing GnRH biosynthesis while modulating Ras/AKT signalling dynamics. Notably, hypothalamic RASA1's effect on regulating ovarian functions and hormone homeostasis was confirmed by an AAV‐based in vivo experiment. Crucially, genetic and pharmacological interventions (RASA1 overexpression/AKT inhibition vs. RASA1 knockdown/AKT activation) reciprocally mimicked testosterone‐induced GnRH hypersecretion and GLP‐1RA‐mediated GnRH suppression, respectively, establishing causal relationships within this signalling axis.

Conclusion:

Our findings provide the first evidence of GLP‐1RA's central mechanism in PCOS management, positioning the hypothalamic RASA1/Ras/AKT/GnRH axis as a master regulator of HPG axis homeostasis and unveiling novel therapeutic targets for precision intervention in reproductive neuroendocrinology.

354

News (Medical) associated with Liraglutide

13 Jan 2026

·firstwordpharma.com

FDA moves to strip suicide warnings from GLP-1 labels

The FDA on Tuesday requested the removal of warnings about suicidal ideation and behaviour from the labels of popular GLP-1 receptor agonists used for weight loss. The products that currently include such warnings on their labels are Novo Nordisk's Saxenda (liraglutide) and Wegovy (semaglutide), as well as Eli Lilly's Zepbound (tirzepatide)."Today's…action will ensure consistent messaging across the labeling for all FDA-approved GLP-1 medications," the agency said.After post-marketing reports emerged of some GLP-1 users experiencing thoughts of suicide or self-injury, the FDA launched a review in mid-2023, examining clinical trials, observational studies and case reports, and shared its initial findings in early 2024. The initial review found no link to suicidal thoughts or behaviour, with EU regulators sharing similar findings a few months later.However, the FDA said small case numbers left room for uncertainty, so it conducted a broader meta-analysis across development programmes. The review, which covered 91 placebo-controlled GLP-1 trials involving close to 108,000 patients, has again found no increased risk of suicidal thoughts and behaviour, or related psychiatric events including anxiety, depression, irritability or psychosis, according to the US regulator.Additionally, using FDA Sentinel System claims data, the agency compared over 2.2 million type 2 diabetes patients starting GLP-1 agonists or SGLT2 inhibitors between a period from 2015 and 2023. After adjusting for confounders, the agency said there was no greater increased risk of intentional self-harm seen among GLP-1 users, including the subgroup of patients who also had obesity.

13 Jan 2026

·www.drugs.com

FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications

Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications This information is an update to the FDA Drug Safety Communication: Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity issued on January 30, 2024. What Is FDA Doing? FDA is requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications that currently include such language. The affected products are Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide). This action follows a comprehensive FDA review that found no increased risk of SI/B associated with the use of GLP-1 RA medications. Saxenda, Wegovy, and Zepbound are each approved for weight reduction in persons with obesity or overweight. At the time of the original FDA approvals, the labeling for each of these products included information in the Warnings and Precautions section about the potential risk of SI/B. Similar information about SI/B is also included in the labeling of other types of weight loss medicines and is based on reports of such events observed with a variety of older medicines used or studied for weight loss. Labeling for GLP-1 RA medications that are approved to improve glycemic (blood sugar) control or other complications in patients with type 2 diabetes mellitus does not currently include information on the risk of SI/B. Today’s FDA action will ensure consistent messaging across the labeling for all FDA-approved GLP-1 RA medications. What Are GLP-1 RAs? GLP-1 RAs are a class of medicines that mimic the effects of a natural hormone called glucagon-like peptide-1 (GLP-1) that is released by the intestine. GLP-1 helps lower blood glucose (sugar) levels after eating and acts in parts of the brain that control appetite and food intake. FDA approved the first GLP-1 RA as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus in 2005. There are now several medications in this drug class on the market. What Should Patients and Caregivers Do? Patients and caregivers should be aware that, after a comprehensive review, FDA found no increased risk of SI/B with the use of GLP-1 RA medications. Patients should continue taking their medication as prescribed and discuss any concerns with their health care professionals. Suicidal ideation occurs when a person is thinking, considering, or planning suicide. Suicidal behavior occurs when a person takes physical actions toward suicide, including suicide attempts or completed suicide (an act of self-harm that causes death). Tell your health care professional if you experience new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior. Call or text 988 or go to the website at https://988lifeline.org/, which provides free support for people in distress 24 hours a day, 7 days a week. What Should Health Care Professionals Do? Health care professionals should be aware that FDA found no increased risk of SI/B with the use of GLP-1 RA medications and is requesting the removal of this Warning and Precaution from the prescribing information for the GLP-1 RA medications (Saxenda, Wegovy, and Zepbound) that include such language. Health care professionals should be prepared to discuss with patients that FDA has found no increased risk after conducting a comprehensive review of the available data. If individuals disclose that they are experiencing SI/B, refer them to mental health professionals for evaluation. What Did FDA Find? The labeling of GLP-1 RA medications approved for weight reduction in persons with obesity or overweight contains information in the Warnings and Precautions section regarding a potential risk of SI/B. Similar information about SI/B is also included in the labeling of other types of weight loss medicines and is based on reports of such events observed with a variety of older medicines used or studied for weight loss. In July 2023, after receiving postmarketing reports of SI/B in patients taking GLP-1 RA medications, FDA initiated further investigation of the potential risk of SI/B for GLP-1 RA medications. FDA performed a preliminary review of clinical trial and postmarketing data, including observational studies and case reports, and publicly reported those findings in its January 2024 Drug Safety Communication. The initial review of GLP-1 RA clinical trial data did not find an association between the use of GLP-1 RAs and the occurrence of SI/B. However, because of the small number of cases of SI/B observed in individual trials, there was considerable uncertainty in the risk estimate. To address this concern, FDA performed a comprehensive meta-analysis of clinical trials across GLP-1 RA drug development programs to improve the precision of the risk estimate. The meta-analysis assessed the risk of SI/B comparing GLP1 RA medications to placebo. There were 91 placebo-controlled GLP-1 RA medication trials in the metaanalysis that included 107,910 patients (60,338 treated with a GLP-1 RA and 47,572 treated with placebo). The results did not show an increased risk for SI/B or for other relevant psychiatric adverse events such as anxiety, depression, irritability, or psychosis. In addition, FDA conducted a retrospective cohort study using administrative healthcare claims data from the FDA Sentinel System to compare the risk of intentional self-harm between new users of GLP-1 RAs and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus. The study population included 2,243,138 users (1,161,983 initiated on a GLP-1 RA and 1,081,155 initiated on a SGLT2i) from 10 data partners during the period between October 1, 2015, and September 20, 2023. After controlling for baseline confounders in the study, FDA did not find an increased risk of intentional self-harm in GLP-1 RA users compared to SGLT2i users. Similarly, FDA did not find an increased risk in the subgroup of patients with both type 2 diabetes mellitus and obesity. FDA also reviewed published observational and pooled studies evaluating the relationship between GLP1 RAs and SI/B, and related outcomes. Our review concluded that the totality of these studies does not support a causal relationship between the use of GLP-1 RAs and the occurrence of SI/B. Therefore, consistent with these findings, FDA is requesting that application holders remove information regarding the risk of SI/B from the labeling of GLP-1 RA medications that currently include such language. How Do I Report Side Effects from GLP-1 RAs? To help FDA track safety issues with medicines, we urge patients and health care professionals to report side effects involving GLP-1 RAs or other medicines to the FDA MedWatch program using the information in the “Contact FDA” box at the bottom of this page. How Can I Get New Safety Information on Medicines I’m Prescribing or Taking? To help FDA track safety issues with medicines, we urge patients and health care professionals to report side effects involving GLP-1 RAs or other medicines to the FDA MedWatch program using the information in the “Contact FDA” box at the bottom of this page. Contact FDA For More Info 855-543-DRUG (3784) and press 4 druginfo@fda.hhs.gov Report a Serious Problem to MedWatch Complete and submit the report Online. Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178. Source: FDA

Drug ApprovalClinical ResultNDA

07 Jan 2026

·www.drugs.com

Ozempic, Wegovy Might Lower Colon Cancer Risk

WEDNESDAY, Jan. 7, 2026 — Ozempic and Wegovy might help people avoid colon cancer as well as promote weight loss or control diabetes, a new study says. People who took a GLP-1 drug were 36% less likely to get colon cancer than people who took aspirin, according to findings scheduled for presentation Saturday at a meeting of the American Society of Clinical Oncology in San Francisco. “While aspirin has been studied for colorectal cancer prevention, its modest benefit and bleeding risks limit its use,” said lead researcher Dr. Colton Jones , a hematology and oncology fellow at the University of Texas-San Antonio. “GLP-1 receptor agonists, now widely prescribed for diabetes and obesity, may offer a safer option for both metabolic control and cancer prevention,” Jones said in a news release. It’s estimated that 150,000 American were diagnosed with colon cancer in 2025 and more than 50,000 died of the disease, researchers said in background notes. Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. The best-known GLP-1 drugs are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). For the new study, researchers analyzed health records for more than 281,000 people drawn from a commercial health care database. Half were taking a GLP-1, and the other half aspirin. Researchers followed the GLP-1 group for about six years, and the aspirin group for about five years. Results showed a 36% lower risk of colon cancer among those taking a GLP-1 drug. Benefits were even greater — a nearly 42% lower risk — among people whose family or personal history put them at higher risk of colon cancer, researchers said. Those taking GLP-1 drugs also were less likely to suffer side effects like kidney damage, stomach ulcers or GI bleeding than those on aspirin, researchers said. However, diarrhea and abdominal pain were more common among those taking GLP-1 drugs. Researchers warned that the overall benefit for any one person was small. Statistics showed that more than 2,000 people would need to take a GLP-1 drug for one person to have a lower risk of colon cancer. However, an estimated 6% of Americans are taking GLP-1 drugs, researchers said. That could mean as many as 20 million Americans already are using GLP-1s, and subsequently benefiting from lower colon cancer risk. As a whole, GLP-1s reduced risk of colon cancer, but when studied individually only semaglutide, liraglutide and dulaglutide had a significant effect, researchers said. Tirzepatide did not show the same significance. The research team next plans to validate its findings in clinical trials. “GLP-1 receptor agonists may have benefits far beyond the waistline,” said Dr. Joel Saltzman , vice chair of regional oncology at Taussig Cancer Center, Cleveland Clinic, who reviewed the findings. “These findings show that they may be an important part of cancer prevention treatment strategies as well,” he continued in a news release. "The preventive benefits of aspirin, nonsteroidal anti-inflammatory drugs and statins in the development of colorectal cancer have been investigated for years. This real-world study suggests that the GLP-1 receptor agonists may have an exciting role in this area.” Salzman said further research is a priority to understand the promise of these drugs to help prevent cancer. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Sources American Society of Clinical Oncology, news release, Jan. 5, 2026

Clinical ResultASCO

100 Deals associated with Liraglutide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Liraglutide	A10BJ02	DB06655

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	Novo Nordisk, Inc.	23 Dec 2014
Overweight	United States	Novo Nordisk, Inc.	23 Dec 2014
Diabetes Mellitus, Type 2	European Union	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Iceland	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Liechtenstein	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Norway	Novo Nordisk A/S	30 Jun 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebrovascular Disorders	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Chronic heart failure	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Coronary Disease	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Peripheral Vascular Diseases	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Polycystic Ovary Syndrome	Phase 3	United States	Novo Nordisk A/S	26 Sep 2018
Binge-Eating Disorder	Phase 3	United States	Novo Nordisk A/S	29 Sep 2017
Prader-Willi Syndrome	Phase 3	United States	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	Australia	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	Canada	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	France	Novo Nordisk A/S	09 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03948347 (LAMP, Pubmed \| JAMA Intern Med) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Ischemic Attack, Transient \| Acute Ischemic Stroke	636	Liraglutide	hfcpfbfggo(fbctlveppy) = tmdmaviubp rjcqjgelbh (dwcikbevyn ) View more	Positive	03 Nov 2025
				Control	hfcpfbfggo(fbctlveppy) = qupcfabmbh rjcqjgelbh (dwcikbevyn ) View more
NCT03260881 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease	38	liraglutide (Study Group)	lkntplvhwu(xtwnddkaqg) = ipwmxlhwek psxvczunaw (xqwobxkmyv, 0.60) View more	-	08 Jul 2025
				placebo (Control Group)	lkntplvhwu(xtwnddkaqg) = clquelrxks psxvczunaw (xqwobxkmyv, 2.3) View more
NCT02516657 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	5	Liraglutide	poebzpkqaz(hgwaoqnfhz) = pchmkmrsrn wxrbbczheo (irkdelkrok, 35) View more	-	20 Apr 2025
NCT04881110 (STARDUST, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	60	Liraglutide (Liraglutide Group)	tcfqfidplq(glmzgcgxrm) = kzcfixvqvh jmwypgeysk (peivonycfp, 5.9) View more	-	03 Mar 2025
				Control (Control Group)	tcfqfidplq(glmzgcgxrm) = oxnnuwjsbk jmwypgeysk (peivonycfp, 4.8) View more
ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	bwnrxbhokd(jhvhdzhndb) = uhjgbvdolx pqnplffqoe (ipmzytmlba )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	bwnrxbhokd(jhvhdzhndb) = jescsmmokr pqnplffqoe (ipmzytmlba )
Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	boyswqtihe(pqcuzjpkzj) = jsphsoviru xqxclnqyto (dtuggubkxq )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	boyswqtihe(pqcuzjpkzj) = ymdogmtttv xqxclnqyto (dtuggubkxq )
NCT02098395 \| NCT01836523 (ADJUNCT ONE and ADJUNCT TWO, Pubmed \| J Diabetes Sci Technol)	Phase 3	Diabetes Mellitus, Type 1 C-peptide	-	Liraglutide 1.8 mg	oldzncfeuv(vqqozmcprr) = ptllslalse tmzlqjxofk (ovwlnmndrt ) View more	-	24 Dec 2024
				Liraglutide 1.2 mg	oldzncfeuv(vqqozmcprr) = bszxpyzvnw tmzlqjxofk (ovwlnmndrt ) View more
NCT06439056 (NEWS)	Phase 1	Diabetes Mellitus, Type 2	3	利拉鲁肽-NEX-22A	rgeiybkkfq(uyzxrxzmgl) = Clinical results have reached the endpoint rpylttufrh (tzdyrkufih ) View more	Positive	22 Nov 2024
NCT04883346 (LBODP002, CTgov)	Phase 2	Obesity	34	Liraglutide	rsiwszrwuu = shsrqlcsum nbvjtkigdb (dxefobqzbi, wtkdzsqjnl - nunmiesgke) View more	-	20 Nov 2024
NCT01794143 (Pubmed \| PLoS One)	Phase 3	Diabetes Mellitus, Type 2	-	Glargine	wjspixrsgh(udxcvpbnge) = panpigjvcj damkfzzond (lzsafpsfja ) View more	Positive	15 Nov 2024
				Glimepiride	wjspixrsgh(udxcvpbnge) = suhrbwhjwf damkfzzond (lzsafpsfja ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis